Revance (RVNC)

Executive Summary

Revance Therapeutics is a commercial-stage biotechnology company focused on innovative neuromodulator products, with its lead asset, daxibotulinumtoxinA (DAXXIFY), approved for aesthetic use (glabellar lines) and under regulatory review for therapeutic indications. DAXXIFY's prolonged duration of effect (up to 6 months) differentiates it from competitors like Botox and Dysport, driving adoption in the aesthetics market. The company's commercial execution has shown steady quarter-over-quarter revenue growth, supported by a focused sales force and partnerships. In neurology, Revance is advancing DAXXIFY for cervical dystonia and migraine prevention, leveraging its proprietary peptide technology for improved stability and safety. Despite competitive pressures and manufacturing complexities, the company maintains a strong cash position to fund operations through key milestones.

Upcoming Catalysts (preview)

• Q2 2026FDA approval decision for DAXXIFY in cervical dystonia75% success
• Q3 2026Phase 3 topline results for DAXXIFY in migraine prevention60% success
• Q4 2026Resolution of patent litigation with Allergan/AbbVie regarding Botox50% success